Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

ESMO 2023

More Like This

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies

PR Newswire associated0

Qilu Pharmaceutical to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

HanchorBio to Present at the ESMO Immuno-Oncology 2023 Annual Congress

(Graphic: Business Wire)

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development